News article view

Press releases

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections

Intravacc announces a $633K grant from CARB-X to develop a preventive Neisseria gonorrhoeae (NG) vaccine. Gonorrhea, the second most reported bacterial STI, affected 82 million globally in 2020, with limited antibiotic options. CARB-X supports Intravacc's innovative meningococcal outer membrane vesicle (OMV) vaccine, targeting gonococcal antigens for enhanced efficacy. Dr. Erin Duffy, CARB-X R&D Chief, highlights the project's potential to prevent the disease and combat global antibiotic resistance. Dr. Jan Groen, CEO of Intravacc, underscores the project's significance in addressing the antimicrobial resistance epidemic.

Download Press Release

Contact us

You can send us an email:

Reach out to Business Development:

Or pick up the phone: 
+31 30 792 03 00

You can also just fill out the contact form on the right.

We look forward to hearing from you!


Contact form

Subscribe to our newsletter